Back Pain Relief Innovation a Success in Germany

LIVERPOOL, U.K. - March 31, 2016 - PRLog -- LumbaCurve International have won their first substantial export order from Germany for their revolutionary back pain relief device, previously showcased at the Medica International Trade Fair in Dusseldorf. After trials with LumbaCurve, Cologne based AtoZ-CRO GmbH have signed an exclusive distributor agreement for the sale of LumbaCurve through their consumer healthcare subsidiary in Germany.

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO), with 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.

The latest version, LumbaCurve LC3, has successfully completed independent clinical trials and been found to be significantly more effective than NHS standard guidelines (NICE) for the treatment of simple mechanical low back pain. Indeed, based on patient reported pain rating scales (NPRS), LumbaCurve was found to provide pain relief some six times greater than the comparison control group after just 7 days. An abstract of these results was presented at the Society for Back Pain Research (SBPR) and was published in The Bone and Joint Journal.

LumbaCurve focuses  on the lumbar region (L4 / L5 / S1) where most back pain occurs, initially providing a passive gravity assisted traction (PGAT), with LumbaCurve acting as a fulcrum to stretch or extend the lower back to separate or decompress the vertebral joints, thus relieving pressure on the inter-vertebral discs. A gentle pelvic rocking motion attempts to mobilise the facet joints, whilst the LumbaCurve surface design delivers an element of shiatsu or acupressure stimulation. LumbaCurve is registered as a Class I medical device that can be used by both manual healthcare professionals or by individuals for self help.

LumbaCurve CEO David Pegg commented, "We are really proud to have our first distribution agreement and export order from Germany and are particularly excited that we have AtoZ-CRO as partners, who were introduced to us through the Enterprise Europe Network. Its pleasing that a company with such an extensive history and pedigree in clinical research has recognised and selected LumbaCurve as an effective back pain relief product for it's portfolio"

"It's also an indication of the growing overseas interest in LumbaCurve with current enquiries from several European countries and Canada. In the UK LumbaCurve is shortly to be featured on QVC TV which should give us further exposure in the domestic consumer healthcare market."

For more information on LumbaCurve back pain products vist http://www.lumbacurve.com